The 5-Gene-Multiplex 0.1% AF cfDNA in Plasma product from SensID is a highly specialized and essential tool for liquid biopsy assays, widely used in both diagnostic and research settings. This product is specifically designed to target a selection of crucial genetic mutations, which are often implicated in a variety of cancers, including lung, breast, colorectal, and melanoma. The mutations included in this multiplex are AKT1, BRAF, KRAS, PIK3CA, and ERBB2, all of which play significant roles in cancer development and therapeutic decisions.

The 5-Gene-Multiplex 0.1% AF cfDNA in Plasma product contains these mutations at a 0.1% allelic frequency (AF), providing a valuable positive control standard for critical applications like digital PCR and next-generation sequencing (NGS). It is an indispensable tool for validating and developing sequencing protocols such as Whole Genome Sequencing (WGS), Amplicon Sequencing, and PCR protocols. Additionally, this product is ideal for determining the detection limits of various methods and ensuring high-confidence variant calling, which is crucial for the accuracy of genomic analyses.

The specific mutations featured in the 5-Gene-Multiplex 0.1% AF cfDNA in Plasma include:

• AKT1 (p.E17K),
• BRAF (p.V600E),
• KRAS (multiple variants),
• PIK3CA (p.E545K, p.H1047R),
• ERBB2 (p.Y772_A775dup).

These mutations are directly linked to important targeted therapies. For example, BRAF mutations, such as p.V600E, are associated with treatment options like vemurafenib, while KRAS mutations play a crucial role in the efficacy of cetuximab therapy. Similarly, mutations in PIK3CA and AKT1 also guide personalized treatment choices for patients.

With its ability to simulate real-world genetic variability, this 5-Gene-Multiplex 0.1% AF cfDNA in Plasma product ensures that diagnostic assays, especially those used in liquid biopsy testing, deliver precise and reliable results, which are essential for the development of personalized cancer therapies.